1 active not recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
Follow utomilumab: new trials by email Literature Review of utomilumab trials Research Report on utomilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Avelumab, Lorlatanib, Talazoparib - Advanced Malignancies, NSCLC | Phase 3 | Active not recruiting | Pfizer | 77 | 2021-09-29 | 2026-10-20 |
| Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Avelumab, Utomilumab, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 3 | Terminated | Pfizer | 29 | 2016-12-16 | 2020-12-17 |
Lymphoma, Large B-Cell, Diffuse (1) · Ovarian Neoplasms (1)
Pfizer (2)
Australia (2) · Belgium (2) · Italy (2) · Poland (2) · South Korea (2) · Spain (2) · United Kingdom (2) · United States (2) · Canada (1) · Denmark (1) · France (1) · Hungary (1) · Israel (1) · Japan (1) · Mexico (1)
2016 (1), 2023 (1)